These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18166813)

  • 41. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
    Ramírez C; Vargas G; González B; Grossman A; Rábago J; Sosa E; Espinosa-de-Los-Monteros AL; Mercado M
    Eur J Endocrinol; 2012 Jan; 166(1):21-6. PubMed ID: 21993154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
    Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
    Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
    Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
    Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study.
    Dal J; Klose M; Heck A; Andersen M; Kistorp C; Nielsen EH; Bollerslev J; Feldt-Rasmussen U; Jørgensen JOL
    Eur J Endocrinol; 2018 Jan; 178(1):65-74. PubMed ID: 28993415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal.
    Yu N; Wang L; Yang H; Pan H; Duan L; Zhu H
    J Clin Pharm Ther; 2022 Jun; 47(6):835-840. PubMed ID: 35167717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.
    Freda PU; Bruce JN; Reyes-Vidal C; Singh S; DeLeon Y; Jin Z; Khandji AG; Cremers S; Post KD
    Pituitary; 2021 Apr; 24(2):170-183. PubMed ID: 33124000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
    Petersenn S; Houchard A; Sert C; Caron PJ;
    Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.